Skip to main content

Table 2 Characteristics of subjects with and without new digital ulcer (DU) development during follow-up

From: Association between baseline clinical and imaging findings and the development of digital ulcers in patients with systemic sclerosis

Patient characteristics at baseline

n = 761

Patients with new DUs

(n = 22)

Patients without new DUs

(n = 54)

p value

Odds ratio

95%CI; p value for cut-off

♀: n (%)

17 (77.3%)

45 (83.3%)

ns

  

Mean age in years (± SD) at

 -Enrollment

56 (± 12.9)

56 (± 15.0)

ns

  

 -Raynaud’s onset

43 (± 14.4)

42 (± 16.4)

ns

  

 -Onset of first non-Raynaud’s symptom

45 (± 14.7)

46 (± 15.2)

ns

  

Smoking

 -Current smokers, n (%)

5 (22.7%)

6 (11.1%)

ns

  

 -Mean pack years (± SD)

13.66 (± 16.38)

8.040 (± 13.4)

ns

  

dcSSc, n (%)

13 (59.1%)

14 (25.9%)

0.0087

4.1

1.5–11.7; p = 0.0087

Mean modified Rodnan skin score (± SD)

13.4 (± 9.4)

6.7 (± 6.9)

0.0008

9.43

3.0–29.2; p < 0.0001

ACR/EUSTAR score (± SD)

19.7 (± 4.0)

15.6 (± 4.1)

0.0004

8.14

2.5–25.6; p = 0.0003

 -Skin involvement

  -Thickening prox. of MCP, n (%)

12 (54.5%)

13 (24.1%)

   

  -Sclerodactyly, n (%)

9 (40.9%)

33 (9.1%)

0.0308

3.85

1.3-10.8; p = 0.0154

  -Puffy fingers, n (%)

1 (4.5%)

6 (61.1%)

   

  -Sine scleroderma

0

2 (3.7%)

   

 -Digital tip ulcers, n (%)

16 (72.7%)

20 (37.0%)

0.0058

4.5

1.5–13.5

 -Pitting scars, n (%)

18 (81.8%)

22 (40.7%)

0.0020

6.5

1.9–22.0

 -Teleangiectesia, n (%)

17 (77.3%)

43 (79.6%)

ns

  

 -Abnormal capillaroscopy, n (%)

22 (100%)

50 (96.2%)

ns

  

 -PAH, n (%)

6 (27.3%)

4 (7.8%)

0.0570

4.4

1.1–17.6

 -Interstitial lung disease, n (%)

10 (45.5%)

16 (29.6%)

ns

  

 -Raynaud phenomenon, n (%)

22 (100%)

54 (100%)

ns

  

 -ACA pos., n (%)

8 (36.4%)

17 (31.5%)

ns

  

 -Scl70 pos., n (%)

9 (40.9%)

22 (40.7%)

ns

  

 -RNAP III pos., n (%)

2 (9.1%)

1 (1.9%)

ns

  

Medications

 -Iloprost

14 (63.6%)

29 (53.7%)

ns

  

 -Bosentan

6 (27.3%)

5 (9.3%)

ns

  

 -Oral vasodilators2

18 (81.8%)

32 (59.3%)

ns

  

Capillaroscopy pattern

 -Early, n (%)

0 (0%)

13 (24.1%)

0.0265

18.66

1.1-326.4; p = 0.0035

 -Active, n (%)

11 (50.0%)

16 (29.6%)

 -Late, n (%)

11 (50.0%)

21 (38.9%)

 -Non-SSc, n (%)

0 (0%)

2 (3.7%)

 -Not done, n (%)

0 (0%)

2 (3.7%)

  1. CI confidence interval, dcSSc diffuse limited cutaneous systemic sclerosis, ns not significant
  2. 1Baseline cohort: n = 79, 3 drop-outs
  3. 2ACE inhibitors, AT1 blockers, PDE5 inhibitors, calcium channel blockers, alpha1 antagonists
  4. 3Cut-off > 8 points
  5. 4Cut-off > 20 points
  6. 5Thickening proximal of MCP compared to other/no skin involvement
  7. 6Cut-off types, active and late